BAY94-9027 PK Study Comparing to Another Long Acting Product

Inclusion Criteria: * Males, age 18 to 65 years. * Subjects with Severe Hemophilia A with a documented plasma FVIII level of \< 1% * ≥ 150 exposure days with FVIII concentrate(s) as supported by medical records Exclusion Criteria: * Evidence of current or past inhibitor antibody: * History of any congenital or acquired coagulation disorders other than hemophilia A. * Platelet count \<75,000/mm\*3. * Abnormal renal function (serum creatinine \>2 x the upper limit of the normal range). * Active liver disease verified by medical history or persistently elevated alanine aminotransferase or aspartate aminotransferase \>5 x the upper limit of the normal range or severe liver disease as evidenced by, but not limited to any of the following: International Normalized Ratio \>1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.